- Top Workplaces
- UCB Inc.
UCB Inc.
At UCB, we come together to work, laser-focused, on a simple question: How will this create value for people living with severe diseases? Patient value is not just what we say, but how we live. How we do business – from discovery to development to delivery – has been transformed and redesigned around the patient’s individual experience. Patients are at the heart of everything we do, inspiring us and driving our scientific discovery. By fulfilling our commitment and providing patients a meaningful experience, more impactful solutions are on the horizon.
With a team of approximately 10,880 employees and operations in nearly 40 countries, we are a global biopharmaceutical company investing more than a quarter of our revenue in cutting-edge scientific research. Global headquarters are in Brussels, Belgium, with U.S. headquarters in Atlanta, Georgia and sites in Raleigh and Durham, North Carolina, Boston, Massachusetts, Seattle, Washington, California, and Washington, D.C.
With a team of approximately 10,880 employees and operations in nearly 40 countries, we are a global biopharmaceutical company investing more than a quarter of our revenue in cutting-edge scientific research. Global headquarters are in Brussels, Belgium, with U.S. headquarters in Atlanta, Georgia and sites in Raleigh and Durham, North Carolina, Boston, Massachusetts, Seattle, Washington, California, and Washington, D.C.
Purpose
UCB is a global biopharmaceutical company focused on severe diseases that have significant unmet needs. By putting patients at the heart of everything we do, we enable people to live their best lives, delivering impactful solutions patients value.
Vision
UCB’s ambition is to transform the lives of people living with severe diseases. We focus on neurology, immunology, and rare disease disorders – putting patients at the center of our world. We are Inspired by Patients. Driven by Science.
UCB is continuously working to advance science and embrace new knowledge. We are leveraging scientific advances and skills in areas such as genetics, biomarkers and human biology. Patients inspire us to bring them value through cutting-edge science, innovative drugs, and practical solutions – so that they and their carers can get on with their lives
UCB is continuously working to advance science and embrace new knowledge. We are leveraging scientific advances and skills in areas such as genetics, biomarkers and human biology. Patients inspire us to bring them value through cutting-edge science, innovative drugs, and practical solutions – so that they and their carers can get on with their lives
Mission
At UCB, we come together every day to work, laser-focused, on a simple question: How will this create value for people living with severe diseases? Patient value is not just what we say, but how we live. It is our culture of care, embodied by our patient value strategy. That’s because how we do business – from discovery to development to delivery – has been transformed and redesigned around the patient and their individual experience. Patients are at the heart of everything we do, inspiring us, driving our scientific discovery, and leading us to rethink the patient experience beyond the medicine. By fulfilling our commitment, driving innovation, and providing patients a meaningful experience, more impactful solutions are on the horizon.
Additional Culture Details
As UCB’s largest affiliate, we have around 1,900 U.S.-based employees.
- $31.4B in economic impact in the last five years.
- UCB continues to expand its U.S. footprint, including a planned $5 billion investment in biologics manufacturing and innovation
- 8 UCB offices across California, Georgia, Massachusetts, North Carolina, Washington, and Washington, D.C.
- 4,000+ enrollees in our active clinical studies
- 15 FDA approvals or indication expansions in recent years
- Globally, we invest about a quarter of our revenue every year in R&D
- In the U.S., about 25-30% of our employees are dedicated to R&D
- $31.4B in economic impact in the last five years.
- UCB continues to expand its U.S. footprint, including a planned $5 billion investment in biologics manufacturing and innovation
- 8 UCB offices across California, Georgia, Massachusetts, North Carolina, Washington, and Washington, D.C.
- 4,000+ enrollees in our active clinical studies
- 15 FDA approvals or indication expansions in recent years
- Globally, we invest about a quarter of our revenue every year in R&D
- In the U.S., about 25-30% of our employees are dedicated to R&D
Values
- From Noise To Signal
- As we navigate uncertainty, we make sense of the world around us to detect opportunities that others don't.
Recent Awards
Company Snapshots
